Zhong, Wen-Zhao
Yan, Hong-Hong http://orcid.org/0000-0002-6228-2096
Chen, Ke-Neng
Chen, Chun
Gu, Chun-Dong
Wang, Jun
Yang, Xue-Ning
Mao, Wei-Min
Wang, Qun
Qiao, Gui-Bin
Cheng, Ying http://orcid.org/0000-0001-9908-597X
Xu, Lin
Wang, Chang-Li
Chen, Ming-Wei
Kang, Xiao-Zheng
Yan, Wan-Pu
Liao, Ri-Qiang
Yang, Jin-Ji
Zhang, Xu-Chao
Liu, Si-Yang
Zhou, Qing
Wu, Yi-Long http://orcid.org/0000-0002-3611-0258
Funding for this research was provided by:
Chinese Thoracic Oncology Group Shanghai Roche Pharmaceutical Ltd
Article History
Received: 3 May 2022
Revised: 8 December 2022
Accepted: 8 December 2022
First Online: 24 February 2023
Competing interests
: Y.-L.W. reports receiving speaker bureau fees from AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Roche AG, Boehringer Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, and Sanofi and research grants from AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., and Roche AG. W.-Z.Z. reports receiving speaker fees from AstraZeneca and Roche. All other authors declare no competing interests.